Deals Update (05/2007)
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
You may also be interested in...
Based on top-line Phase III data for garadacimab, CSL is preparing to submit the Factor XIIa inhibitor for US FDA approval for monthly prophylaxis of hereditary angioedema and expand the firm’s HAE franchise.
FDA says warning to VPR Brands could be its first move to reign in sales of nicotine gummies. Statements on brand’s site could indicate sales of nicotine gummies for smoking cessation are on the rise even though the claim isn’t approved.
An Oregon factory’s citations received by the FDA are among the most common violations the agency finds during inspections, ORA Office of Human and Animal Food Operations deputy director said.